Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently…
Browsing: Nivolumab
Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD,…
Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients…
AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered…
Author: Dr Michiel van der Heijden (on-camera comments) – Courtesy of ESMO.org Checkmate 901, a study focusing on first-line treatment…
In a conversation hosted by Allen Wilbanks, Solange Peters, MD, PhD, a full professor and chair of medical oncology specializing…
Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to…
Updates in Lymphoma: Advancements in Treatment Strategies Date: August 12, 2023Presenter: Elizabeth Brem, MD (Clinical Associate Professor) In the ever-evolving…
Dr. Kevin Harrington, Phd of the Royal Marsden Hospital, The Institute of Cancer Research, London, is the author of this…
Cody Peer, PhD, from the National Institutes of Health, is conducting a randomized research study comparing the dosing intervals of…
Cholangiocarcinoma: Ipilimumab and Nivolumab Combo  MOASC Poster Session 2022 (Cholangiocarcinoma Ipilimumab Nivolumab) Hello, my name is Dalia Kaakour (clinical…